TapewireFind a company

person · Reporting owner

Kuhlmann Shirley R.

Disclosed activity across 1 company

Tapewire entity
82297
SEC CIK
0001734919

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

COLLEGIUM PHARMACEUTICAL, INC

Report date March 04, 2025 · Filed March 06, 2025

Section 16 reporting ended · disclosed 2025-03-06. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect108,137 Ending reported balance After 2025-03-06 transaction · row 4
4 source rows · reconciled sequence

Row 1 · 2025-03-04 · Exercise / conversion · Acquired 40,000 · Balance 194,204

Row 2 · 2025-03-04 · Sale · Disposed 40,000 · Balance 154,204

F1: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.

Row 3 · 2025-03-05 · Sale · Disposed 20,000 · Balance 134,204

F2: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.18, inclusive.

Row 4 · 2025-03-06 · Sale · Disposed 26,067 · Balance 108,137

F3: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.50 to $28.58, inclusive.

Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $24.03 · Expires 2028-04-04Direct0 Reported balance After 2025-03-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2025-03-04 · Exercise / conversion · Disposed 40,000 · Balance 0

F4: The option is fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.

F2: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.18, inclusive.

F3: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.50 to $28.58, inclusive.

F4: The option is fully vested and exercisable.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 06, 2025 Filed Mar 6, 2025 18:48 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 26,067 $28.50 $742,945.99
Disclosure

SEC source: 0001062993-25-004776 · form4.xml · nonDerivative · entry 4

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,137

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.50 to $28.58, inclusive.

Read SEC document
March 05, 2025 Filed Mar 6, 2025 18:48 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 20,000 $28.03 $560,528.00
Disclosure

SEC source: 0001062993-25-004776 · form4.xml · nonDerivative · entry 3

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,204

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.18, inclusive.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 18:48 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionStock Option (Right to Purchase) · Derivative 40,000 $0.00 Strike: $24.03 $0.00
Disclosure

SEC source: 0001062993-25-004776 · form4.xml · derivative · entry 5

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2028-04-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 18:48 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 40,000 $28.08 $1,123,160.00
Disclosure

SEC source: 0001062993-25-004776 · form4.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,204

F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 18:48 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionCommon Stock 40,000 $24.03 $961,200.00
Disclosure

SEC source: 0001062993-25-004776 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,204

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 16:09 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 25,149 $30.52 $767,547.48
Disclosure

SEC source: 0001062993-25-002175 · form4.xml · nonDerivative · entry 4

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,204

F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 16:09 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 9,826 $30.52 $299,889.52
Disclosure

SEC source: 0001062993-25-002175 · form4.xml · nonDerivative · entry 3

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,353

F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 16:09 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 29,030 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-002175 · form4.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 189,179

F2 · shares: Effective February 10, 2025, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 29,030 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 16:09 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 40,965 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-002175 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,149

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2026, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

Read SEC document
January 10, 2025 Filed Jan 14, 2025 16:12 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionStock Option (Right to Purchase) · Derivative 27,500 $0.00 Strike: $21.34 $0.00
Disclosure

SEC source: 0001062993-25-000761 · form4.xml · derivative · entry 4

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,500 shares

Expires 2030-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
January 10, 2025 Filed Jan 14, 2025 16:12 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 6,100 $33.64 $205,220.47
Disclosure

SEC source: 0001062993-25-000761 · form4.xml · nonDerivative · entry 3

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,184

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.42 to $33.41, inclusive.

Read SEC document
January 10, 2025 Filed Jan 14, 2025 16:12 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 21,400 $32.87 $703,407.30
Disclosure

SEC source: 0001062993-25-000761 · form4.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,284

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.43 to $33.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Read SEC document
January 10, 2025 Filed Jan 14, 2025 16:12 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionCommon Stock 27,500 $21.34 $586,850.00
Disclosure

SEC source: 0001062993-25-000761 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 146,684

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024.

Read SEC document
September 06, 2024 Filed Sep 6, 2024 17:52 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 977 $37.46 $36,594.12
Disclosure

SEC source: 0001062993-24-016277 · form4.xml · nonDerivative · entry 3

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,184

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.455 to $37.4592, inclusive.

Read SEC document
September 05, 2024 Filed Sep 6, 2024 17:52 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 2,400 $39.14 $93,941.04
Disclosure

SEC source: 0001062993-24-016277 · form4.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,161

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.01 to $39.20, inclusive.

Read SEC document
September 05, 2024 Filed Sep 6, 2024 17:52 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 16,848 $38.18 $643,256.64
Disclosure

SEC source: 0001062993-24-016277 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,561

F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.00 to $38.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.

Read SEC document
June 03, 2024 Filed Jun 5, 2024 16:06 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 700 $33.22 $23,254.00
Disclosure

SEC source: 0001062993-24-011979 · form4.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,409

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2024.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.19 to $33.31, inclusive.

Read SEC document
June 03, 2024 Filed Jun 5, 2024 16:06 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 24,300 $32.55 $790,926.12
Disclosure

SEC source: 0001062993-24-011979 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 140,109

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2024.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.18 to $33.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 16:14 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 10,610 $33.70 $357,557.00
Disclosure

SEC source: 0001062993-24-003167 · form4.xml · nonDerivative · entry 4

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,409

F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 16:14 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 21,146 $33.70 $712,620.20
Disclosure

SEC source: 0001062993-24-003167 · form4.xml · nonDerivative · entry 3

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,019

F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 16:14 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 33,247 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-003167 · form4.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,165

F2 · shares: Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 33,247 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 16:14 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 43,400 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-003167 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,918

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

Read SEC document
November 27, 2023 Filed Nov 29, 2023 16:32 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionStock Option (Right to Purchase) · Derivative 25,600 $0.00 Strike: $15.90 $0.00
Disclosure

SEC source: 0001062993-23-021604 · form4.xml · derivative · entry 3

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,600 shares

Expires 2029-01-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
November 27, 2023 Filed Nov 29, 2023 16:32 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 25,600 $25.78 $660,014.08
Disclosure

SEC source: 0001062993-23-021604 · form4.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,518

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.76 to $25.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 27, 2023 Filed Nov 29, 2023 16:32 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionCommon Stock 25,600 $15.90 $407,040.00
Disclosure

SEC source: 0001062993-23-021604 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 145,118

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023.

Read SEC document
June 26, 2023 Filed Jun 28, 2023 16:08 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 1,363 $22.53 $30,715.07
Disclosure

SEC source: 0001062993-23-014095 · form4.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,518

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.39 to $22.59, inclusive.

Read SEC document
June 26, 2023 Filed Jun 28, 2023 16:08 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 16,621 $21.65 $359,917.78
Disclosure

SEC source: 0001062993-23-014095 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,881

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.26 to $22.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Read SEC document
February 13, 2023 Filed Feb 14, 2023 17:18 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 21,811 $26.88 $586,279.68
Disclosure

SEC source: 0001062993-23-003479 · form4.xml · nonDerivative · entry 5

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,502

F5 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 28, 2022.

F6 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.485 to $27.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6).

Read SEC document
February 10, 2023 Filed Feb 14, 2023 17:18 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 7,755 $26.75 $207,446.25
Disclosure

SEC source: 0001062993-23-003479 · form4.xml · nonDerivative · entry 4

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,313

F4 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units.

Read SEC document
February 10, 2023 Filed Feb 14, 2023 17:18 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 16,291 $26.75 $435,784.25
Disclosure

SEC source: 0001062993-23-003479 · form4.xml · nonDerivative · entry 3

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,068

F3 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
February 10, 2023 Filed Feb 14, 2023 17:18 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 25,739 Not disclosed Not disclosed
Disclosure

SEC source: 0001062993-23-003479 · form4.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,359

F2 · price: Effective February 10, 2023, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 25,739 performance share units granted in the issuer's three prior fiscal years.

Read SEC document
February 10, 2023 Filed Feb 14, 2023 17:18 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 48,125 $0.00 $0.00
Disclosure

SEC source: 0001062993-23-003479 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,620

F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2024, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.

Read SEC document
September 15, 2022 Filed Sep 16, 2022 16:22 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 38,589 $18.07 $697,303.23
Disclosure

SEC source: 0001062993-22-019618 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,495

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2022 and amended on August 15, 2022.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.91 to $18.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

Read SEC document
August 11, 2022 Filed Aug 15, 2022 16:34 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 300 $20.01 $6,003.00
Disclosure

SEC source: 0001062993-22-017994 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,084

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2022.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

Read SEC document
March 16, 2022 Filed Mar 18, 2022 16:03 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 734 $18.99 $13,938.66
Disclosure

SEC source: 0001062993-22-008131 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,384

F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
February 10, 2022 Filed Feb 14, 2022 18:37 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 4,212 $17.63 $74,257.56
Disclosure

SEC source: 0001062993-22-004319 · form4.xml · nonDerivative · entry 4

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,118

F4 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units.

Read SEC document
February 10, 2022 Filed Feb 14, 2022 18:37 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 6,967 $17.63 $122,828.21
Disclosure

SEC source: 0001062993-22-004319 · form4.xml · nonDerivative · entry 3

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,330

F3 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
February 10, 2022 Filed Feb 14, 2022 18:37 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 14,341 Not disclosed Not disclosed
Disclosure

SEC source: 0001062993-22-004319 · form4.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,297

F2 · price: On February 10, 2022, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 14,341 performance share units granted in the issuer's three prior fiscal years.

Read SEC document
February 10, 2022 Filed Feb 14, 2022 18:37 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 56,700 $0.00 $0.00
Disclosure

SEC source: 0001062993-22-004319 · form4.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,956

F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2023, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.

Read SEC document
September 16, 2021 Filed Sep 20, 2021 16:03 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 734 $19.67 $14,437.78
Disclosure

SEC source: 0001879789-21-000003 · edgar.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,256

F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
May 10, 2021 Filed May 12, 2021 16:06 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 7,000 $22.77 $159,390.00
Disclosure

SEC source: 0001192482-21-000419 · edgar.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,990

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021.

Read SEC document
March 16, 2021 Filed Mar 18, 2021 16:07 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 734 $24.69 $18,122.46
Disclosure

SEC source: 0001192482-21-000251 · edgar.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,990

F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
February 10, 2021 Filed Feb 12, 2021 16:16 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 3,695 $25.95 $95,885.25
Disclosure

SEC source: 0001192482-21-000150 · edgar.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,724

F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
February 10, 2021 Filed Feb 12, 2021 16:16 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 2,163 $25.95 $56,129.85
Disclosure

SEC source: 0001192482-21-000150 · edgar.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,419

F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of performance stock units.

Read SEC document
January 20, 2021 Filed Jan 21, 2021 16:29 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 6,081 $24.45 $148,680.45
Disclosure

SEC source: 0001192482-21-000085 · edgar.xml · nonDerivative · entry 3

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,582

F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

Read SEC document
January 20, 2021 Filed Jan 22, 2021 16:05 UTC Amendment COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 6,081 $24.45 $148,680.45
Disclosure

SEC source: 0001192482-21-000094 · edgar.xml · nonDerivative · entry 3

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,582

F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

Read SEC document
January 19, 2021 Filed Jan 21, 2021 16:29 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantStock Option (Right to Purchase) · Derivative 129,600 $0.00 Strike: $24.06 $0.00
Disclosure

SEC source: 0001192482-21-000085 · edgar.xml · derivative · entry 4

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,600

Underlying: Common Stock · 129,600 shares

Expires 2031-01-19

F4 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2022, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer.

Read SEC document
January 19, 2021 Filed Jan 21, 2021 16:29 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 6,772 Not disclosed Not disclosed
Disclosure

SEC source: 0001192482-21-000085 · edgar.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,663

F2 · price: On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 6,772 performance share units granted in two prior years.

Read SEC document
January 19, 2021 Filed Jan 21, 2021 16:29 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 45,360 $0.00 $0.00
Disclosure

SEC source: 0001192482-21-000085 · edgar.xml · nonDerivative · entry 1

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,891

F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.

Read SEC document
January 19, 2021 Filed Jan 22, 2021 16:05 UTC Amendment COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 6,772 Not disclosed Not disclosed
Disclosure

SEC source: 0001192482-21-000094 · edgar.xml · nonDerivative · entry 2

Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,663

F2 · price: On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 6,772 performance share units granted in two prior years.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.